ORYZON GENOMICS, S.A. «...678910...» Page 10 out of 13 27/05/2021 07:21 ORYZON GENOMICS, S.A. Announcement of general shareholders’ meeting Call of the Ordinary General Shareholders’ Meeting of Oryzon Genomics, S.A. Register number: 9625 07/05/2021 17:47 ORYZON GENOMICS, S.A. Other relevant information La Sociedad remite información sobre los resultados del primer trimestre de 2021 Register number: 9305 12/04/2021 11:02 ORYZON GENOMICS, S.A. Board of Directors Regulations La sociedad remite el reglamento del Consejo de Administración Register number: 8517 09/03/2021 08:03 ORYZON GENOMICS, S.A. Other relevant information ORYZON presents vafidemstat 12-month clinical data from its Phase IIa clinical trials ETHERAL and REIMAGINE-AD in Alzheimer’s at the virtual AD/PD-2021 conference Register number: 7847 22/02/2021 19:46 ORYZON GENOMICS, S.A. Other relevant information Oryzon remite nota de prensa sobre resultados del ejercicio 2020 Register number: 7200 22/02/2021 12:56 ORYZON GENOMICS, S.A. Half-yearly financial reports and audit reports/limited audit review La sociedad remite información financiera del segundo semestre de 2020 Register number: 7190 22/02/2021 12:50 ORYZON GENOMICS, S.A. Annual report on directors´ remunerations La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2020 Register number: 7189 22/02/2021 12:44 ORYZON GENOMICS, S.A. Annual corporate governance report La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2020 Register number: 7188 11/02/2021 15:11 ORYZON GENOMICS, S.A. Other relevant information ORYZON granted Orphan Drug Designation by FDA for iadademstat for the treatment of acute myeloid leukemia Register number: 7073 07/12/2020 07:57 ORYZON GENOMICS, S.A. Other relevant information ORYZON presents additional positive efficacy data of iadademstat from its ongoing Phase IIa clinical trial in acute myeloid leukemia at ASH-2020 Register number: 6062 Page 10 out of 13 «...678910...»